×
About 1,658 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  411 results

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

May 20th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Study of Mast Cell Precursors
https://clinicaltrials.gov/ct2/show/NCT00001756

May 20th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

Differential mast cell mediators in Systemic Mastocytosis and Hereditary Alpha-tryptase...
https://doi.org/10.1016/j.jaci.2022.04.025
The Journal of Allergy and Clinical Immunology; Giannetti MP, Godwin G et. al.

May 14th, 2022 - Patients with systemic mastocytosis often have symptoms of mast cell activation which is associated with elevated levels of urinary mast cell mediator metabolites. Patients with hereditary alpha-tryptasemia (HαT) may present with symptoms of mast ...

Massive release of Th2 cytokines induced a cytokine storm during a severe mast cell act...
https://doi.org/10.1016/j.jaci.2022.04.023
The Journal of Allergy and Clinical Immunology; Boehm T, Ristl R et. al.

May 4th, 2022 - In subjects with systemic mastocytosis the number of mast cells is elevated manifold. These patients frequently suffer unpredictable and recurrent life-threatening mast cell activation (MCA) events. Our aim was to analyze the derangements of chemo...

Single-cell transcriptomics reveals the identity and regulators of human mast cell prog...
https://doi.org/10.1182/bloodadvances.2022006969
Blood Advances; Wu C, Boey D et. al.

May 3rd, 2022 - Mast cell accumulation is a hallmark of a number of diseases including allergic asthma and systemic mastocytosis. IgE-mediated crosslinking of the FceRI receptors causes mast cell activation and contributes to disease pathogenesis. The mast cell l...

see more →

Guidelines  1 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

see more →

Drugs  191 results see all →

Clinicaltrials.gov  16 results

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

May 20th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Study of Mast Cell Precursors
https://clinicaltrials.gov/ct2/show/NCT00001756

May 20th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
https://clinicaltrials.gov/ct2/show/NCT03214666

Apr 1st, 2022 - This is a multi-center Phase I/II clinical trial of GTB-3550 (CD16/IL-15/CD33) tri-specific killer cell engager (TriKE®) for the treatment of CD33-expressing high risk myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanc...

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03580655

Mar 28th, 2022 - This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neopl...

Cromoglycate Adjunctive Therapy for Outpatients With Schizophrenia
https://clinicaltrials.gov/ct2/show/NCT03794076

Mar 8th, 2022 - Schizophrenia (SZ) extracts a heavy personal and public health cost, primarily because there is no effective treatment. Though many drugs are currently available, the majority provide only partial relief for psychotic phenomena and none guarantee ...

see more →

News  44 results

Avapritinib Approved in Europe for Advanced Systemic Mastocytosis
https://www.onclive.com/view/avapritinib-approved-in-europe-for-advanced-systemic-mastocytosis

Mar 25th, 2022 - The European Commission has expanded the current indication for avapritinib (Ayvakyt) to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast ...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

EU Panel Recommends Avapritinib for Advanced Systemic Mastocytosis
https://www.onclive.com/view/eu-panel-recommends-avapritinib-for-advanced-systemic-mastocytosis

Jan 31st, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended to expand the current indication for avapritinib (Ayvakyt) to include use as a single agent in the treatment of adult patients with aggressive sy...

New Trials in Leukemia: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962196

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

Sep 15th, 2021 - SYSTEMIC MASTOCYTOSIS (SM) is a rare disease that often first presents on the skin. It is characterized by the overaccumulation of mast cells (MCs), which can then penetrate such internal organs as bone marrow (BM).¹ Challenges in identification a...

see more →